U.S. markets closed
  • S&P Futures

    3,962.75
    +3.75 (+0.09%)
     
  • Dow Futures

    33,084.00
    +52.00 (+0.16%)
     
  • Nasdaq Futures

    12,932.00
    -12.50 (-0.10%)
     
  • Russell 2000 Futures

    2,167.60
    +12.20 (+0.57%)
     
  • Crude Oil

    61.77
    +0.21 (+0.34%)
     
  • Gold

    1,704.80
    -7.40 (-0.43%)
     
  • Silver

    24.66
    -0.11 (-0.45%)
     
  • EUR/USD

    1.1773
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.7210
    +0.0610 (+3.67%)
     
  • Vix

    20.74
    +1.88 (+9.97%)
     
  • GBP/USD

    1.3781
    +0.0017 (+0.12%)
     
  • USD/JPY

    109.9600
    +0.1520 (+0.14%)
     
  • BTC-USD

    57,377.22
    +1,824.58 (+3.28%)
     
  • CMC Crypto 200

    1,154.20
    +41.05 (+3.69%)
     
  • FTSE 100

    6,736.17
    -4.42 (-0.07%)
     
  • Nikkei 225

    29,369.16
    -15.36 (-0.05%)
     

SHAREHOLDER ALERT: BLU MPLN IQDNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / March 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

BELLUS Health Inc. (NASDAQ:BLU)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/bellus-health-inc-investigation-loss-submission-form?prid=14189&wire=1
Lead Plaintiff Deadline: May 17, 2021
Class Period: September 5, 2019 - July 5, 2020

Allegations against BLU include that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.

Multiplan Corporation F/K/A Churchill Capital Corp. Iii (NYSE:MPLN)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/multiplan-corporation-f-k-a-churchill-capital-corp-iii-loss-submission-form?prid=14189&wire=1
Lead Plaintiff Deadline: April 26, 2021
Class Period: July 12, 2020 - November 10, 2020

Allegations against MPLN include that: (a) MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, a competitor created by one of MultiPlan's largest customers, UnitedHealthcare, which threatened up to 35% of the Company's sales and 80% of its levered cash flows by 2022; (b) sales and revenue declines in the quarters leading up to the Merger were not due to "idiosyncratic" customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan's services and increased competition, as payors developed competing services and sought alternatives to eliminating excessive healthcare costs; (c) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers, who had expressed dissatisfaction with the price and quality of MultiPlan's services and balanced billing practices, causing the Company's to cut its take rate by up to half in some cases; (d) as a result of (a)-(c) above, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; (e) as a result of (a)-(d) above, MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning through pricey acquisitions, including through the purchase of HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger; and (f) as a result of (a)-(e) above, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan's business was worth far less than represented to investors.

Infinity Q Diversified Alpha Fund Institutional Class (NASDAQ:IQDNX)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/infinity-q-diversified-alpha-fund-loss-submission-form?prid=14189&wire=1
Lead Plaintiff Deadline: April 27, 2021
Class Period: December 21, 2018 - February 22, 2021

Allegations against IQDNX include that: (1) Infinity Q's Chief Investment Officer made adjustments to certain parameters within the third-party pricing model that affected the valuation of the swaps held by the Fund; (2) consequently, Infinity Q would not be able to calculate NAV correctly; (3) as a result, the previously reported NAVs were unreliable; (4) because of the foregoing, the Fund would halt redemptions and liquidate its assets; and (5) as a result, the Prospectuses were materially false and/or misleading and failed to state information required to be stated therein.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/638043/SHAREHOLDER-ALERT-BLU-MPLN-IQDNX-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines